First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr plus Ven) vs Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-Up From the GLOW Study

被引：0

作者：

Moreno, Carol ^{[1
]}

Munir, Talha ^{[2
]}

Owen, Carolyn ^{[3
]}

Follows, George ^{[4
]}

Hernandez-Rivas, Jose-Angel ^{[5
]}

Benjamini, Ohad ^{[6
]}

Janssens, Ann ^{[7
]}

Levin, Mark-David ^{[8
]}

Robak, Tadeusz ^{[9
]}

Simkovic, Martin ^{[10
,11
]}

Voloshin, Sergey ^{[12
]}

Vorobyev, Vladimir ^{[13
]}

Yagci, Munci ^{[14
]}

Ysebaert, Loic ^{[15
]}

Qi, Qianya ^{[16
]}

Smith, Emma ^{[16
]}

Srinivasan, Srimathi ^{[17
]}

Schuier, Natasha ^{[18
]}

Baeten, Kurt ^{[19
]}

Caces, Donne Bennett ^{[16
]}

Niemann, Carsten ^{[20
]}

Kater, Arnon ^{[21
]}

机构：

[1] Autonomous Univ Barcelona, Josep Carreras Leukaemia Res Inst, Hosp Santa Creu & St Pau, Barcelona, Spain

[2] St James Hosp, Leeds, England

[3] Tom Baker Canc Clin, Calgary, AB, Canada

[4] Addenbrookes Hosp, Cambridge, England

[5] Univ Complutense, Hosp Univ Infanta Leonor, Madrid, Spain

[6] Sheba Med Ctr, Ramat Gan, Israel

[7] Univ Ziekenhuizen Leuven, Leuven, Belgium

[8] Albert Schweitzer Hosp, Dordrecht, Netherlands

[9] Med Univ Lodz, Copernicus Mem Hosp, Lodz, Poland

[10] Univ Hosp, Fac Med Hradec Kralove, Dept Internal Med Haematol 4, Hradec Kralove, Czech Republic

[11] Charles Univ Prague, Hradec Kralove, Czech Republic

[12] Russian Sci & Res Inst Hematol & Transfusiol, St Petersburg, Russia

[13] SP Botkin Moscow City Clin Hosp, Moscow, Russia

[14] Gazi Univ Tip Fak, Ankara, Turkiye

[15] Inst Univ Canc Toulouse Oncopole, Toulouse, France

[16] Janssen Res & Dev, Raritan, NJ USA

[17] Janssen Res & Dev, Oncol Translat Res, Lower Gwynedd Township, PA USA

[18] Janssen Res & Dev, Dusseldorf, Germany

[19] Janssen Res & Dev, Beerse, Belgium

[20] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark

[21] Univ Amsterdam, Amsterdam Univ Med Ctr, Canc Ctr Amsterdam, Amsterdam, Netherlands

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

CLL; chronic lymphocytic leukemia; ibrutinib; venetoclax; fixed-duration regimen; minimal residual disease (MRD); trial-in-progress;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CLL-487

引用

页码：S356 / S357

页数：2